Clasado Biosciences (‘Clasado’), a global leader in the development of scientifically proven prebiotic ingredients and product solutions for the human gut microbiome, has shared insight on what it believes to be a tipping point for the US prebiotic market. 

The business believes that market conditions are in place for exponential growth as brand innovation and consumer demand align, setting prebiotics up for rapid category growth. Research firm Global Market Insights projects that the US prebiotic market will surpass $9.5Bn by 2027, accelerated by increasing awareness of fiber and rising incidence of gastrointestinal ailments. 

Doug King, Senior Sales Manager North America at Clasado, commented: “Prebiotics are seeing strong traction around the globe, but there is particularly significant potential in North America. The US market has typically been highly influenced by lifestyle trends and a demand for products with scientific backing. Like patterns seen across Europe, consumers in the US are becoming acutely aware of how they can proactively influence their own health. More than ever, they are actively seeking knowledge around health and nutrition, which naturally leads to a focus on gut health. 

“Consumers in the US are looking for health-supporting products that fit easily into everyday routines. For many, this means seeking out improved nutritional profiles from the foods they already purchase every day. Brands and product developers have extremely strong potential on the table for functional foods. Prebiotics, despite their impressive growth, are still relatively new as a standalone ingredient. Being first to market is an incredibly powerful commercial advantage and with prebiotics included as part of new product development, there’s a great deal of opportunity available in areas such as baked goods, snacks and cereals.”

Clasado is the developer and manufacturer of Bimuno®, an award-winning proprietary GOS ingredient available to brands in the food and nutrition categories. The most studied prebiotic of its kind, Bimuno is supported by over 90 scientific publications, including more than 20 clinical studies. 

Designed with versatility front of mind for product developers, Bimuno is extremely stable and benefits from a low effective dose. 

Doug concluded: “The number of new product development projects we’re working on including Bimuno are extremely encouraging. It’s the ideal time for health and nutrition brands to explore how new product launches can be made simple and effective with an ingredient that ticks every box for the consumer and formulator alike.”

Demonstrating the impressive scientific backing behind its development, Bimuno has recently been awarded ‘Ingredient of the Year: Prebiotic’ at the NutraIngredients Europe Awards and is shortlisted in the US Awards under the same category. 

To find out more about the impressive science behind Bimuno and the varied commercial benefits of its inclusion new product development, please visit www.clasado.com or contact info@clasado.com